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Abstract 
Background.  Fatigue is often the complaint that initiates thyroid function investigation. Most 
available data related to fatigue and hypothyroidism involved patients with subclinical 
hypothyroidism where fatigue was not the primary outcome.  This study investigated the 
association between TSH levels and fatigue and if there was a target TSH interval that was 
associated with lower incidence of fatigue in patients with hypothyroidism.   
Methods.  An analytic, retrospective cohort study design assessed the relationship between TSH 
levels and fatigue.  All adult patients at one endocrinology clinic who were diagnosed with 
hypothyroidism between January 1, 2006 and December 31, 2007 were included.  Diagnoses 
were confirmed by biochemical testing.  Data were abstracted from the clinic’s electronic 
medical record.  Fatigue status was self-reported by the subject during examination by the 
endocrinologist.  Fatigue status and TSH levels were obtained twice: at diagnosis and during the 
first follow-up visit.   
Results.  A total of 135 patients met the inclusion criteria.  After treatment, all patients had 
reductions in TSH levels.  Those subjects reporting relief from fatigue tended to be males (p = 
0.003), had lower TSH levels at follow-up (p < 0.001), had larger TSH differences from baseline 
(p =0.007), and had a primary diagnosis of acquired hypothyroidism (p < 0.001).  Females were 
2.9 times more likely to report persistent fatigue than males.  Patients with primary diagnosis of 
thyroiditis were 3 times more likely to report persistent fatigue than those with acquired 
hypothyroidism.   
Conclusions.  The observed relief from fatigue after treatment correlated with a higher TSH 
reduction compared to patients with persistent fatigue.  It was unclear if fatigue relief was related 
to the level of TSH reduction (TSH difference) or to a lower absolute TSH level reached after 
treatment.         
KJM 2012; 5(2):51-57. 
 
 
Introduction 
Hypothyroidism is a common condition 
affecting 4.6% of the US population.1  
Hypothyroidism manifests different levels of 
severity and presents with a wide inter-
individual range of clinical and biochemical 
signs and symptoms.2 Most of the clinical 
manifestations of hypothyroidism are related 
to the lack of thyroid hormone. The lack of 
thyroid hormone results in a generalized 
slowing  of  metabolic  processes  leading  to   
 
fatigue, cold intolerance, weight gain, 
generalized slowing, and bradycardia.3,4 
Advances and improvements in the 
diagnosis of hypothyroidism have meant 
that a larger number of patients are being 
detected with the condition.5 Endocrino-
logists titrate thyroid hormone replacement 
based on thyroid stimulating hormone 
(TSH) levels. Despite the improvement in 
laboratory diagnosis, follow-up, and 
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monitoring, patient’s satisfaction has not 
improved.6 
Fatigue and obesity are often the 
complaints that initiates thyroid function 
investigation.3,4 Fatigue is reported in 21% 
of patient encounters in primary care.7  
Testing in the fatigued patient is increasing, 
although the yield is low, particularly with 
thyroid testing. Fatigue poses a diagnostic 
challenge for clinicians with its extensive 
differential diagnosis. Fatigue symptoms 
usually begin long before presentation and 
often remain after treatment. Thyroid 
function testing is recommended only when 
symptoms of fatigue are prolonged and 
debilitating.4  
Most available data related to fatigue 
and hypothyroidism involved patients with 
subclinical hypothyroidism where fatigue 
was not the primary outcome.2,8,9 For 
example, symptoms, including fatigue, in 
patients with subclinical hypothyroidism 
improved with hormone replacement.2  Two 
clinical scores assessing symptoms and 
signs of hypothyroidism (Billewicz and 
Zulewski scores) improved significantly.  
However, no specific interval or target for 
the TSH level was suggested as a result of 
these scores. Another randomized trial 
concluded that there were no clinically 
relevant benefits from six months of 
thyroxine treatment in women with mild 
subclinical hypothyroidism.2   
The aim of treatment for hypothyroidism 
is to restore the patient’s TSH value to 
normal. Some patients may feel better only 
when their TSH level below 2.5 mU/l, the 
lower half of the reference range.4 In fact, 
quality of life measures (including fatigue) 
are reduced distinctly in thyroid cancer 
patients undergoing thyroid hormone 
withdrawal.10 Thus, low TSH levels are 
important for symptom reduction in 
hypothyroid patients. However, the target 
TSH that may improve symptoms of fatigue 
is unclear. 
The purpose of this study was to 
investigate the association between TSH 
levels and fatigue and to investigate if there 
is a target TSH range that was associated 
with lower incidence of fatigue in patients 
with hypothyroidism.  The research question 
was:  Is there an association between fatigue 
and TSH levels in patients with 
hypothyroidism on hormonal replacement 
therapy? It was hypothesized that a specific 
range of TSH will be associated with less 
fatigue. 
 
Methods 
Study design. An analytic, retrospective 
cohort study design was used to assess the 
relationship between TSH levels and fatigue. 
The study was approved by the university 
Institutional Review Board. 
Setting and data source. The study took 
place at an endocrinology clinic in Wichita, 
Kansas.  Clinic staff provided names of all 
adult patients who were diagnosed with a 
type of hypothyroidism (by JH) between 
January 1, 2006 and December 31, 2007. 
One investigator (IEB) reviewed charts of 
eligible participants and diagnoses were 
confirmed by biochemical testing. Data were 
abstracted from the clinic’s electronic 
medical record.   
Participants. Eligible participants were 
adult clinic patients, aged 18 or over, with 
diagnoses of primary hypothyroidism 
according to the International Classification 
of Diseases, 9th Revision (ICD-9). 
Specifically, clinic staff identified patients 
with the following ICD-9 codes: 244: 
Acquired hypothyroidism (Ablation), 245: 
Thyroiditis (Autoimmune) and 244.9: 
Unspecified hypothyroidism (NOS). 
Inclusion criteria were: a) documented 
reported fatigue prior to treatment, b) 
documented fatigue status at three-month 
follow-up, c) hormone replacement therapy, 
and d) record of TSH levels from both initial 
and three-month follow-up visits. Exclusion 
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criteria were: a) patients with other known 
causes for fatigue at the time of diagnosis 
(i.e., cancer, including thyroid cancer, 
uncontrolled diabetes, sleep apnea, advanced 
chronic obstructive pulmonary disease, 
fibromyalgia, clinical depression, among 
others), b) patients on T3 (liothyronine), and 
c) those who obtained biochemical testing at 
other facilities. 
Variables. The outcome of interest was 
fatigue status following hormone replace-
ment therapy. Fatigue status was self-
reported as present or absent by the subject 
during examination and interview by the 
endocrinologist. Fatigue status and TSH 
levels were obtained twice: at diagnosis 
(baseline) and during the first follow-up 
visit, usually at 3 months (post-treatment). 
Fatigue status was identified as those 
patients reporting fatigue at follow-up 
(Persistent Fatigue) and those reporting no 
fatigue (Relief from Fatigue). In an effort to 
control for information bias associated with 
self-reported fatigue, only those patients 
with a documented complaint of fatigue 
prior to treatment were included in the 
analyses. Reduction in TSH level was 
calculated by subtracting follow-up levels 
from baseline (TSH difference).  Predictor 
variables were age, body mass index (BMI), 
and TSH difference. Potential confounders/ 
effect modifiers (i.e., sex, type of primary 
diagnosis, and BMI by TSH difference 
interaction) were assessed with multi-
variable analysis. 
Statistical methods. Sample size was 
determined by the number of patients in the 
clinic who met inclusion/exclusion criteria 
during the study period. Quantitative 
variables (age, BMI, and TSH difference) 
were assessed for normality, while 
categorical variables were summarized by 
frequency and/or proportions. Descriptive 
analysis was conducted for patient char-
acteristics and TSH level at baseline and at 
follow-up. Univariate analyses (Kolmo-
gorov-Smirnov, Chi-square or Fisher’s 
Exact Test, risk estimates, Mann-Whitney 
Test) were conducted to compare Persistent 
Fatigue with Relief from Fatigue groups. 
Logistic regression models (Generalized 
Linear Models: binomial probability 
distribution with logit link function) that 
incorporated TSH difference, including 
interactions, were explored.  Criteria for best 
model was based on goodness-of-fit 
measures [i.e., Deviance (closest value to 
one), AIC, and BIC (small-is-better form)].  
Analyses were conducted in PASW 
Statistics 18 (SPSS), IBM Corp., Somers, 
NY. 
 
Results 
Eligible participants included 183 
patients identified with one of the three 
types of hypothyroidism. Of those, 135 
(74%) met the inclusion criteria and were 
included in the final analysis. Table 1 
summarizes patient demographics, TSH 
levels, diagnoses, and univariate analyses by 
fatigue status. Data were sparse and test 
results of the continuous variables (age, 
BMI, TSH levels) by Fatigue Status using 
the Kolmogorov-Smirnov tests were 
inconclusive. However, histograms revealed 
a potential non-Gaussian distribution, 
therefore, non-parametric Mann-Whitney 
exact tests were conducted. Likewise, 
Fisher’s exact tests were reported for gender 
and diagnosis. Results showed significant 
differences for gender, TSH follow-up, TSH 
difference, and diagnosis.   
Those subjects reporting relief from 
fatigue tended to be males more so than 
females (p = 0.003), had lower TSH levels 
at follow-up (p < 0.001), had larger TSH 
difference (p =0.007), and had a primary 
diagnosis of post ablative hypothyroidism (p 
< 0.001). Crude risk estimates showed that 
females were 2.9 times more likely to report 
persistent fatigue than males.  Similarly, 
patients with primary diagnosis of 
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Table 1.  Characteristics of adults with hypothyroidism presenting with fatigue. 
 
thyroiditis were three times more likely to 
report persistent fatigue than those with post 
ablative hypothyroidism.  The conflicting 
results for gender by diagnosis by fatigue 
status were interesting, such that, of the 30 
females diagnosed with thyroiditis, 90% 
reported persistent fatigue, whereas of the 
18 males with thyroiditis, 83.3% reported 
relief from fatigue, although data were 
sparse. 
Figure 1 demonstrates the relationship 
between fatigue status and TSH levels at 
baseline and follow-up, with regard to 
primary diagnosis. With the exception of 
two female patients (top: age 46 with BMI = 
21, bottom: age 63, BMI =34), a linear (and 
lower) trend was observed for relief from 
fatigue compared with persistent fatigue. 
Table 2 shows results from the final 
Generalized Linear Model. Goodness of fit 
measures were Deviance = 1.434, AIC = 
129.76, BIC = 141.38, with gender, 
diagnosis, and TSH difference included in 
the model. All were statistically significant. 
Greater reductions in TSH level were 
associated with relief from fatigue, while 
controlling for the effects of gender and 
diagnosis (RRadj = 1.22, p = 0.033). In 
addition, results showed that patients 
diagnosed with acquired (post ablation) 
hypothyroidism were more than 14 times as 
likely to report relief from fatigue than those 
diagnosed with thyroiditis.  
More than 51% of patients were 
diagnosed with acquired hypothyroidism (69 
out of 135, and of these 55 were female); 
moreover, the greatest reduction in TSH 
levels, as measured by median TSH 
difference, were observed within this group 
(see Figure 2). 
 
Discussion 
The study showed that thyroid hormonal 
replacement was associated with improve-
ment in reported fatigue in the majority of 
patients. This observation was expected, as 
most of the symptoms of hypothyroidism are 
related to thyroid hormone deficiency. 
 Relief from 
Fatigue 
Persistent  
Fatigue 
 
Gender (%) n = 87 n = 48 p RRcrude 
   Female 58 (66.7) 43 (89.6) 0.003 2.9 
   Male 29 (33.3) 5 (10.4)  ref 
     
Diagnosis (%)     
   Acquired (post ablation) 
Hypothyroidism 
69 (79.3) 18 (37.5) <  0.001 ref 
   Thyroiditis 18 (20.7) 30 (62.5)  3.0 
   Unspecified Hypothyroidism -- --  
   
 Median (range)   
Age 51.0 (33, 74) 54.5 (32.0, 73.0) 0.793  
BMI 27.0 (19.0, 
36.0) 
28.0 (19.0, 36.0) 0.33  
TSH baseline 10.8 (6.2, 16.0) 10.4 (6.2, 14.8) 0.971  
TSH follow-up 1.0 (0.5, 7.4) 1.85 (0.3, 8.6) < 0.001  
TSH difference 9.5 ( 3.2, 14.6) 7.9 (2.6, 13.7) 0.007  
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Figure 1. Relationship between fatigue status, TSH levels, and diagnosis. 
 
 
Table 2.  Multivariable logistic regression analysis of relief from fatigue compared with 
persistent fatigue adjusted for gender diagnosis and reduction in TSH level (TSH difference). 
  95% Wald CI 
 RRadj p Lower Upper 
Gender     
    Female 0.05 < 0.001 0.01 0.22 
    Male ref    
Diagnosis     
    Ablation 14.09 < 0.001 4.73 42.00 
    Autoimmune ref    
TSH difference 1.22 0.033 1.02 1.46 
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Figure 2.  Fatigue status by gender, diagnosis, and median TSH difference.  
 
Despite treatment and the decrease of 
TSH value, fatigue persisted in a number of 
patients. Interestingly, the observed relief 
from fatigue after treatment correlated with 
a higher TSH reduction compared to patients 
with persistent fatigue. This observation 
may be related to presence of a higher 
concentration of thyroid hormone in patients 
reporting improvement in fatigue, thereby 
resulting in more inhibition of TSH 
secretion. It was unclear if fatigue relief was 
related to the level of TSH reduction (TSH 
difference) or to a lower absolute TSH level 
reached after treatment. 
In addition, patients with autoimmune 
thyroiditis were less likely to report 
improvement of fatigue compared to the 
post ablation group. The observed variability 
of response to treatment between patients 
with thyroiditis and patients with post 
ablation hypothyroidism could be related to 
the association of autoimmune thyroiditis to 
other autoimmune disorders that may have 
been clinically silent. However, groups were 
imbalanced and data were sparse. More than 
51% of patients were diagnosed with 
acquired (post ablation) hypothyroidism (69 
out of 135, and of these 55 were female); 
moreover, the greatest reduction in TSH 
levels, as measured by median TSH 
difference, were observed within this group 
(see Figure 2). Thus, evaluating interactions 
among variables were not statistically 
feasible. 
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These results were limited in several 
ways. Data were obtained from one 
endocrinology clinic by one endocrinologist. 
Initial TSH levels differed widely. Fatigue 
was self-reported and no validated measure 
of fatigue was used. Fatigue was assessed 
only at diagnosis and the three-month 
follow-up. A longer follow-up is needed to 
assess the effect of thyroid hormonal 
replacement therapy on fatigue.   
Despite these limitations, the study 
results are interesting. It showed variable 
response to treatment by gender and by 
diagnosis. It is possible that female patients 
and patients with a diagnosis of thyroiditis 
are less likely to respond to conventional 
treatment and require a higher dose of 
thyroid hormonal replacement therapy. The 
study was not designed to answer this 
question. Future studies should consider a 
prospective cohort design that match 
patients on diagnosis type, then reassess the 
effects of gender and TSH levels on various 
levels of fatigue. 
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